Matthew Blackburn

Matthew Blackburn has a diverse work experience spanning several companies. Matthew started their career as a Student Manager at RIT Dining Commons, where they were responsible for training and managing student employees in food service. From 2010 to 2013, they also worked as a Research Student at Cleveland Clinic, focusing on a project related to vascular atrophy due to spaceflight, which received funding from NASA and NIH.

In 2014, Matthew joined GSK as a Research Scientist Co-Op, where they conducted experiments to produce lentivirus particles and carried out various expression studies using mammalian cell lines. Matthew also performed cell line profiling in response to compound and antibody treatments.

After that, Matthew joined WuXi AppTec in 2015 as an Associate Scientist / Study Director. In this role, they provided training on technical expertise and compliance issues in the lab setting. Matthew conducted and directed assays and lab procedures in compliance with guidelines and SOPs. Matthew also served as a study director for multiple assays, including those for Replication Competent Lentivirus (RCL).

In 2017, Matthew moved to WuXi Advanced Therapies, where they worked as a Scientist / Technical Reviewer. Matthew'sresponsibilities included reviewing technical documentation and providing input for regulatory submissions.

Since 2018, Matthew has been working at Abeona Therapeutics. Matthew started as a Scientist and progressed to Senior Scientist before assuming their current role as Associate Director. The details of their responsibilities in these positions are not provided.

Overall, Matthew Blackburn's work experience demonstrates a strong background in scientific research, laboratory techniques, regulatory compliance, and project management.

Matthew Blackburn completed their Bachelor of Science (BS) degree in Biotechnology from Rochester Institute of Technology, where they studied from 2009 to 2013. In 2013, they continued their education at Drexel University College of Medicine, earning a Master of Science (MS) degree in Molecular Medicine, which they completed in 2015.